Beta Blocker vs Calcium Channel Blocker for Stable Angina
(LIVEBETTER Trial)
Trial Summary
What is the purpose of this trial?
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Will I have to stop taking my current medications?
If you are currently taking beta-blockers or calcium channel blockers, you cannot participate in this trial. The trial does not specify about other medications, so it's best to discuss with the trial team.
What evidence supports the effectiveness of beta blockers for treating stable angina?
Research shows that beta blockers like carvedilol, metoprolol, and bisoprolol improve survival and symptoms in heart failure patients, suggesting they may also help with stable angina. These drugs have additional benefits like reducing blood pressure and improving heart function, which can be beneficial for angina.12345
Are beta blockers and calcium channel blockers generally safe for humans?
Beta blockers like metoprolol, bisoprolol, and carvedilol are generally safe with a low risk of serious side effects if used correctly, though they can cause issues like slow heart rate or breathing problems in some cases. Calcium channel blockers are not specifically mentioned in the provided research, but beta blockers have been shown to be safe in large studies for conditions like heart failure.16789
What makes the drug for stable angina unique?
The drug for stable angina is unique because it compares beta blockers, which can have additional benefits like vasodilation and antioxidant properties, with calcium channel blockers. Some beta blockers, like nebivolol, also improve blood vessel function by releasing nitric oxide, which can be beneficial for heart health.35101112
Eligibility Criteria
This trial is for older adults aged 75 and above with stable angina, heart disease, and at least two other chronic conditions. They must be planning to start medical therapy for their heart condition but can't have severe reactions to beta-blockers or calcium channel blockers, nor plans for immediate complete revascularization.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Beta-Blocker or Calcium Channel Blocker therapy as part of the study medication
Follow-up
Participants are monitored for safety and effectiveness after treatment, including cognitive assessments
Ancillary Neurocognitive Study
Extended follow-up to assess cognitive decline and incidence of mild cognitive impairment and probable dementia
Treatment Details
Interventions
- Beta blocker (Beta Blocker)
- Calcium channel blocker (Calcium Channel Blocker)
Beta blocker is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Hypertension
- Heart failure
- Angina
- Arrhythmias
- Migraine
- Glaucoma
- Anxiety disorders
- Hypertension
- Heart failure
- Angina
- Arrhythmias
- Migraine
- Glaucoma
- Anxiety disorders
- Hypertension
- Heart failure
- Angina
- Arrhythmias
- Migraine
- Glaucoma
- Anxiety disorders
- Hypertension
- Heart failure
- Angina
- Arrhythmias
- Migraine
- Glaucoma
- Anxiety disorders
- Hypertension
- Heart failure
- Angina
- Arrhythmias
- Migraine
- Glaucoma
- Anxiety disorders
- Hypertension
- Heart failure
- Angina
- Arrhythmias
- Migraine
- Glaucoma
- Anxiety disorders